141 related articles for article (PubMed ID: 21980956)
1. Overview of alemtuzumab therapy for the treatment of T-cell lymphomas.
Zinzani PL; Corradini P; Gallamini A; Grossi A; Lazzarino M; Marchetti M; Martelli M; Rossi G; Vitolo U
Leuk Lymphoma; 2012 May; 53(5):789-95. PubMed ID: 21980956
[TBL] [Abstract][Full Text] [Related]
2. Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy.
Jiang L; Yuan CM; Hubacheck J; Janik JE; Wilson W; Morris JC; Jasper GA; Stetler-Stevenson M
Br J Haematol; 2009 Apr; 145(2):173-9. PubMed ID: 19236377
[TBL] [Abstract][Full Text] [Related]
3. Alemtuzumab in T-cell malignancies.
Dearden CE; Matutes E; Catovsky D
Med Oncol; 2002; 19 Suppl():S27-32. PubMed ID: 12180489
[TBL] [Abstract][Full Text] [Related]
4. Receptor-directed therapy of T-cell leukemias and lymphomas.
Morris JC; Waldmann TA; Janik JE
J Immunotoxicol; 2008 Apr; 5(2):235-48. PubMed ID: 18569395
[TBL] [Abstract][Full Text] [Related]
5. The role of alemtuzumab in the management of T-cell malignancies.
Dearden C
Semin Oncol; 2006 Apr; 33(2 Suppl 5):S44-52. PubMed ID: 16720203
[TBL] [Abstract][Full Text] [Related]
6. Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H).
Rodig SJ; Abramson JS; Pinkus GS; Treon SP; Dorfman DM; Dong HY; Shipp MA; Kutok JL
Clin Cancer Res; 2006 Dec; 12(23):7174-9. PubMed ID: 17145843
[TBL] [Abstract][Full Text] [Related]
7. Targeting CD52 as a novel therapeutic strategy in angioimmunoblastic T-cell lymphoma.
Dunleavy K; Wilson WH
Leuk Lymphoma; 2010 Sep; 51(9):1583-4. PubMed ID: 20795788
[No Abstract] [Full Text] [Related]
8. Alemtuzumab in peripheral T-cell malignancies.
Dearden C
Cancer Biother Radiopharm; 2004 Aug; 19(4):391-8. PubMed ID: 15453953
[TBL] [Abstract][Full Text] [Related]
9. Alemtuzumab.
Ravandi F; O'Brien S
Expert Rev Anticancer Ther; 2005 Feb; 5(1):39-51. PubMed ID: 15757437
[TBL] [Abstract][Full Text] [Related]
10. Alemtuzumab and CHOP Chemotherapy for the Treatment of Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Center Phase I Study.
Buckstein R; Fraser G; Cheung M; Kukreti V; Kuruvilla J; Imrie K; Piliotis E; Pond G; Windsor J; Ghorab Z; Shuoprasad K; Turner R; Meyer RM; Pritchard K; Walker S; Levine M; Crump M
Clin Lymphoma Myeloma Leuk; 2016 Jan; 16(1):18-28.e4. PubMed ID: 26711181
[TBL] [Abstract][Full Text] [Related]
11. Sustained, durable responses with alemtuzumab in refractory angioimmunoblastic T-cell lymphoma.
Amengual JE; Raphael BG
Leuk Lymphoma; 2010 Jul; 51(7):1347-50. PubMed ID: 20572801
[No Abstract] [Full Text] [Related]
12. Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab.
Baker D; Herrod SS; Alvarez-Gonzalez C; Giovannoni G; Schmierer K
JAMA Neurol; 2017 Aug; 74(8):961-969. PubMed ID: 28604916
[TBL] [Abstract][Full Text] [Related]
13. Alemtuzumab and DHAP (A-DHAP) is effective for relapsed peripheral T-cell lymphoma, unspecified: interim results of a phase II prospective study.
Kim SJ; Kim K; Kim BS; Suh C; Huh J; Ko YH; Kim WS
Ann Oncol; 2009 Feb; 20(2):390-2. PubMed ID: 19211502
[No Abstract] [Full Text] [Related]
14. Mogamulizumab for the treatment of T-cell lymphoma.
Makita S; Tobinai K
Expert Opin Biol Ther; 2017 Sep; 17(9):1145-1153. PubMed ID: 28649848
[TBL] [Abstract][Full Text] [Related]
15. Effective treatment of a peripheral T-cell lymphoma/lymphoepitheloid cell variant (Lennert's lymphoma) refractory to chemotherapy with the CD-52 antibody alemtuzumab.
Zeitlinger MA; Schmidinger M; Zielinski CC; Chott A; Raderer M
Leuk Lymphoma; 2005 May; 46(5):771-4. PubMed ID: 16019517
[TBL] [Abstract][Full Text] [Related]
16. Alemtuzumab in CLL and other lymphoid neoplasms.
Ravandi F; O'brien S
Cancer Invest; 2006 Nov; 24(7):718-25. PubMed ID: 17118783
[TBL] [Abstract][Full Text] [Related]
17. Depletion of CD52-positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune-tolerance promoting CD8 T-cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis.
von Kutzleben S; Pryce G; Giovannoni G; Baker D
Immunology; 2017 Apr; 150(4):444-455. PubMed ID: 27925187
[TBL] [Abstract][Full Text] [Related]
18. A remarkable effect of alemtuzumab in a patient suffering from narcolepsy with cataplexy.
Donjacour CE; Lammers GJ
J Sleep Res; 2012 Aug; 21(4):479-80. PubMed ID: 22142323
[No Abstract] [Full Text] [Related]
19. CD52 expression in T-cell large granular lymphocyte leukemia--implications for treatment with alemtuzumab.
Osuji N; Del Giudice I; Matutes E; Morilla A; Owusu-Ankomah K; Morilla R; Dunlop A; Catovksy D
Leuk Lymphoma; 2005 May; 46(5):723-7. PubMed ID: 16019510
[TBL] [Abstract][Full Text] [Related]
20. Effect of alemtuzumab on neoplastic B cells.
Golay J; Manganini M; Rambaldi A; Introna M
Haematologica; 2004 Dec; 89(12):1476-83. PubMed ID: 15590398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
